The Leukocyte Antibody Prevalence Study‐II (LAPS‐II): a retrospective cohort study of transfusion‐related acute lung injury in recipients of high‐plasma‐volume human leukocyte antigen antibody–positive or –negative components

Abstract

TRALI incidence in recipients of anti-HLA-positive components was relatively low for a lookback study (1 in 170) and was higher than in the control arm, but did not reach significance. Based on this trend, the data are consistent with the likelihood that TRALI risk is decreased by selecting high-volume plasma components for transfusion from donors at low risk of having HLA antibodies.